AR117403A2 - Formulaciones de anticuerpos - Google Patents

Formulaciones de anticuerpos

Info

Publication number
AR117403A2
AR117403A2 ARP190100691A ARP190100691A AR117403A2 AR 117403 A2 AR117403 A2 AR 117403A2 AR P190100691 A ARP190100691 A AR P190100691A AR P190100691 A ARP190100691 A AR P190100691A AR 117403 A2 AR117403 A2 AR 117403A2
Authority
AR
Argentina
Prior art keywords
vla
concentration
binding antibody
composition
seq
Prior art date
Application number
ARP190100691A
Other languages
English (en)
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of AR117403A2 publication Critical patent/AR117403A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica acuosa estable para administrarse subcutáneamente o intravenosamente a un sujeto, caracterizada porque comprende un anticuerpo fijador de VLA-4 en una concentración de 120 a 190 mg/ml, un buffer de fosfato en una concentración de 5 mM a 30 mM, cloruro de sodio en una concentración entre 100 mM y 200 mM, y polisorbato 80 en una cantidad de 0,02% - 0,08% (p/v), en donde la composición tiene pH 5,5 a 6,5, y en donde el anticuerpo fijador de VLA-4 tiene una secuencia de aminoácidos de la cadena liviana de SEQ ID Nº 1 y una secuencia de aminoácidos de la cadena pesada de SEQ ID Nº 2. Reivindicación 2: La composición de la reivindicación 1, caracterizada porque el anticuerpo fijador de VLA-4 es natalizumab.
ARP190100691A 2007-06-14 2019-03-19 Formulaciones de anticuerpos AR117403A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94407607P 2007-06-14 2007-06-14

Publications (1)

Publication Number Publication Date
AR117403A2 true AR117403A2 (es) 2021-08-04

Family

ID=39956053

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080102545A AR067011A1 (es) 2007-06-14 2008-06-13 Formulaciones de anticuerpos
ARP190100691A AR117403A2 (es) 2007-06-14 2019-03-19 Formulaciones de anticuerpos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080102545A AR067011A1 (es) 2007-06-14 2008-06-13 Formulaciones de anticuerpos

Country Status (24)

Country Link
US (3) US20080311119A1 (es)
EP (2) EP3461500A1 (es)
JP (2) JP2010529999A (es)
CN (2) CN101778640A (es)
AR (2) AR067011A1 (es)
AU (1) AU2008266051B2 (es)
BR (1) BRPI0814252B8 (es)
CA (1) CA2690382A1 (es)
CY (1) CY1121208T1 (es)
DK (1) DK2170390T3 (es)
EA (1) EA020456B1 (es)
ES (1) ES2707815T3 (es)
HR (1) HRP20182146T1 (es)
HU (1) HUE041555T2 (es)
IL (1) IL202648B (es)
LT (1) LT2170390T (es)
MX (2) MX2009013593A (es)
NZ (2) NZ582436A (es)
PL (1) PL2170390T3 (es)
PT (1) PT2170390T (es)
SI (1) SI2170390T1 (es)
TR (1) TR201820837T4 (es)
TW (1) TWI614028B (es)
WO (1) WO2008157356A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008409A (es) 2003-02-10 2005-10-05 Elan Pharm Inc Formulacion de inmunoglobulina y metodo para la preparacion de la misma.
JP2012533548A (ja) * 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
EP3345615B1 (en) 2010-03-01 2019-10-16 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HUE035098T2 (en) 2010-04-16 2018-05-02 Biogen Ma Inc Anti-VLA4 Antibodies
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
WO2013006461A1 (en) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
JP6113176B2 (ja) 2011-10-18 2017-04-12 コヒラス・バイオサイエンシズ・インコーポレイテッド キシリトールによって安定化されたエタネルセプト製剤
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
US20150150979A1 (en) * 2012-06-21 2015-06-04 Ucb Pharma, S.A. Pharmaceutical formulation
EA029193B1 (ru) 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
IN2015KN00452A (es) 2012-09-11 2015-07-17 Coherus Biosciences Inc
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
EP3062814A1 (en) * 2013-10-29 2016-09-07 Albumedix A/S Antibody composition
CA2924448C (en) * 2013-11-29 2021-12-14 Genentech, Inc. Antibody selection apparatus and methods
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
JP2017510627A (ja) * 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド 多発性硬化症の併用治療
CA2950241A1 (en) * 2014-06-02 2015-12-10 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of fc fragments
EP3207061A1 (en) * 2014-10-18 2017-08-23 Pfizer Inc Anti-il-7r antibody compositions
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
KR20220034169A (ko) * 2019-07-10 2022-03-17 리제너론 파아마슈티컬스, 인크. 감소된 수준의 숙주 세포 단백질을 포함하는 방법 및 조성물
TW202227483A (zh) * 2020-10-30 2022-07-16 日商衛材R&D企管股份有限公司 醫藥組合物
US20230416373A1 (en) 2020-11-14 2023-12-28 Biogen Ma Inc. Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies
JP2024513974A (ja) 2021-04-13 2024-03-27 バイオジェン・エムエイ・インコーポレイテッド 慢性活動性白質病変／放射線学的孤立性症候群を治療するための組成物及び方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPS62196921A (ja) 1986-02-25 1987-08-31 Nec Corp 位相検出回路
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0678018B1 (en) 1993-01-06 2003-04-09 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2182013C (en) * 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
CN101712720A (zh) 1996-02-09 2010-05-26 艾博特生物技术有限公司 结合人TNFα的人抗体
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001055112A1 (en) 2000-01-27 2001-08-02 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
MXPA05008409A (es) 2003-02-10 2005-10-05 Elan Pharm Inc Formulacion de inmunoglobulina y metodo para la preparacion de la misma.
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
AU2005306399B2 (en) * 2004-11-19 2012-02-09 Biogen Ma Inc. Treatment for multiple sclerosis
EP2053961A4 (en) 2006-08-09 2013-05-01 Biogen Idec Inc METHOD FOR DISPENSING A MEDICAMENT

Also Published As

Publication number Publication date
HUE041555T2 (hu) 2019-05-28
AR067011A1 (es) 2009-09-30
JP2014040424A (ja) 2014-03-06
AU2008266051A2 (en) 2010-02-25
IL202648A0 (en) 2011-08-01
BRPI0814252B1 (pt) 2019-12-10
TWI614028B (zh) 2018-02-11
US20080311119A1 (en) 2008-12-18
CN103977404A (zh) 2014-08-13
SI2170390T1 (sl) 2019-02-28
NZ582436A (en) 2012-06-29
LT2170390T (lt) 2019-01-10
WO2008157356A3 (en) 2009-02-19
DK2170390T3 (en) 2019-01-21
PL2170390T3 (pl) 2019-05-31
ES2707815T3 (es) 2019-04-05
US20120134989A1 (en) 2012-05-31
JP2010529999A (ja) 2010-09-02
EA020456B1 (ru) 2014-11-28
CA2690382A1 (en) 2008-12-24
US9533044B2 (en) 2017-01-03
EP2170390A2 (en) 2010-04-07
BRPI0814252A2 (pt) 2015-04-14
TR201820837T4 (tr) 2019-01-21
AU2008266051B2 (en) 2014-07-31
CN101778640A (zh) 2010-07-14
TW200908995A (en) 2009-03-01
EA201070015A1 (ru) 2010-06-30
BRPI0814252B8 (pt) 2021-05-25
NZ595526A (en) 2013-03-28
MX2020005214A (es) 2020-08-20
EP3461500A1 (en) 2019-04-03
HRP20182146T1 (hr) 2019-02-08
WO2008157356A2 (en) 2008-12-24
AU2008266051A1 (en) 2008-12-24
US20130017193A1 (en) 2013-01-17
MX2009013593A (es) 2010-01-20
IL202648B (en) 2018-04-30
BRPI0814252A8 (pt) 2019-01-29
PT2170390T (pt) 2019-02-12
CY1121208T1 (el) 2020-05-29
EP2170390B1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
AR117403A2 (es) Formulaciones de anticuerpos
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
AR124140A2 (es) Formulaciones de anticuerpos
PE20130579A1 (es) Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
PE20020127A1 (es) Interleuquina 2 estabilizada
AR110731A2 (es) Formulaciones que estabilizan e inhiben la precipitación de composiciones inmunogénicas
RS52913B (en) SUBcutaneous FORMULATION OF ANTI-HER2 ANTIBODIES
PE20091960A1 (es) Compuestos de insulina lispro pegilada
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
PE20071063A1 (es) Formulaciones de proteinas estables
PE20061043A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales
RS54769B1 (sr) Visoko koncentrovane farmaceutske formulacije koje sadrže anti-cd20 antitelo
NZ629204A (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
NZ719036A (en) Anti-pdl1 antibody formulations
AR050353A1 (es) Composicion de anticuerpo her2
PE20071111A1 (es) Metodos para modular el contenido de manosa de proteinas recombinantes
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
NZ630885A (en) Antibody formulation
EA201200490A1 (ru) Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения
EA200702408A1 (ru) Аналоги глюкагонподобного пептида-2 (glp-2)

Legal Events

Date Code Title Description
FC Refusal